Pfizer and Moderna rapidly falling out of favor as Americans' favorite brands: report
By
Ben AdamsMay 27, 2022 08:55am
The Harris PollPfizerModerna TherapeuticsComirnaty
Pfizer and Moderna's mRNA vaccines boosted their visibility in 2021, but, as COVID fears recede, so too does their impact on Americans. ( solarseven/ iStock/ Getty Images Plus)
What a difference a year makes: Pfizer and Moderna were riding high in Americans' minds last year, but a new report from The Harris Poll shows how both have fallen from grace.
In 2021,
Moderna ranked third and Pfizer came in at No. 7 in the annual
Axios survey, undertaken by The Harris Poll, that focuses on Americans’ favorite brands in what it calls the 100 “most visible companies.”
But in 2022, the two are on a downward spiral. Pfizer has dropped 37 places to 44th on the list, while Moderna has fallen out of the top 100 completely. In 2020, Moderna didn’t place at all, while Pfizer was 61st.
The difference in 2021 was, of course, the companies’ rollout of their respective mRNA COVID vaccines, Comirnaty and Spikevax, two of the most highly anticipated products of a generation as they could help the world return to normality amid the deadly pandemic.
But now we are more than two years into the pandemic, and, as these vaccines have helped reduce the overall risk of death and severe outcomes from the disease, the initial emergency state of COVID has receded.